Crenessity Solution
NDC Package 70370-5250-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Crenessity (crinecerfont) solution is cRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH). . This formulation utilizes a solution delivery system. Marketed by Neurocrine Biosciences, Inc., this product is identified by NDC 70370-5250 and is authorized under FDA application NDA218820.

Identification & Billing

NDC Package Code
70370-5250-1
Package Description
30 mL in 1 BOTTLE
Product Code
70370-5250
11-Digit Billing Format
70370525001
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
30 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Crenessity
Non-Proprietary Name
Crinecerfont
Substance Name
Crinecerfont
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
CRINECERFONT 50 mg/mL
Usage Information
CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH). 

Regulatory & Marketing

Labeler Name
Neurocrine Biosciences, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA218820
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-13-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70370-5250-1 identifies a specific commercial package of 30 ml in 1 bottle of Crenessity, a human prescription drug labeled by Neurocrine Biosciences, Inc.. This product is billed per "ML" milliliter and contains an estimated amount of 30 billable units per package. This solution is formulated for oral use and contains crinecerfont as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Neurocrine Biosciences, Inc. on December 13, 2024. The current certification is valid through December 31, 2026.

How is this Neurocrine Biosciences, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70370525001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70370-5250-1
11-Digit CMS (5-4-2)
70370-5250-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.